Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: Role for heme oxygenase-1 down-modulation

Chemico-Biological Interactions

Volumn 177, Issue 1, 2009, Pages 12-20

  Bernuzzi, Francesca ^a   Recalcati, Stefania ^a   Alberghini, Alessandra ^a   Cairo, Gaetano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anthracyclines; Cell death; Chemotherapy; Heart; Oxidative stress

Indexed keywords

DOXORUBICIN; HEME OXYGENASE 1; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DEATH; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; HEART MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; APOPTOSIS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME OXYGENASE-1; MYOCYTES, CARDIAC; NECROSIS; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER;

EID: 57349125695     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.09.012     Document Type: Article

References (42)

1. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1998) 900-905
2. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
3. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727-741
4. Sawyer D.B., Fukazawa R., Arstall M.A., and Kelly R.A. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 84 (1999) 257-265
5. Kotamraju S., Konorev E.A., Joseph J., and Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. 275 (2000) 33585-33592
6. L'Ecuyer T., Allebban Z., Thomas R., and Vander Heide R. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H2057-H2064
7. Wang S., Kotamraju S., Konorev E., Kalivendi S., Joseph J., and Kalyanaraman B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J. 367 (2002) 729-740
8. Wang G.W., Klein J.B., and Kang Y.J. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J. Pharmacol. Exp. Ther. 298 (2001) 461-468
9. Green P.S., and Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim. Biophys. Acta 1588 (2002) 94-101
10. Spallarossa P., Garibaldi S., Altieri P., Fabbi P., Manca V., Nasti S., Rossettin P., Ghigliotti G., Ballestrero A., Patrone F., Barsotti A., and Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 37 (2004) 837-846
11. Dorr R.T. Cytoprotective agents for anthracyclines. Semin. Oncol. 23 (1996) 23-34
12. Hershko C., Link G., Tzahor M., and Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk. Lymphoma 11 (1993) 207-214
13. Link G., Tirosh R., Pinson A., and Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. 127 (1996) 272-278
14. Miranda C.J., Makui H., Soares R.J., Bilodeau M., Mui J., Vali H., Bertrand R., Andrews N.C., and Santos M.M. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102 (2003) 2574-2580
15. Minotti G., Cairo G., and Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB J. 13 (1999) 199-212
16. Ladas E.J., Jacobson J.S., Kennedy D.D., Teel K., Fleischauer A., and Kelly K.M. Antioxidants and cancer therapy: a systematic review. J. Clin. Oncol. 22 (2004) 517-528
17. Corna G., Santambrogio P., Minotti G., and Cairo G. Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J. Biol. Chem. 279 (2004) 13738-13745
18. Recalcati S., Tacchini L., Alberghini A., Conte D., and Cairo G. Oxidative stress-mediated down-regulation of rat hydroxyacid oxidase 1, a liver-specific peroxisomal enzyme. Hepatology 38 (2003) 1159-1166
19. Alberghini A., Recalcati S., Tacchini L., Santambrogio P., Campanella A., and Cairo G. Loss of the von Hippel Lindau tumour suppressor disrupts iron homeostasis in renal carcinoma cells. J. Biol. Chem. 280 (2005) 30120-30128
20. Motterlini R., Foresti R., Intaglietta M., and Winslow R.M. NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium. Am. J. Physiol. 270 (1996) H107-H114
21. Spallarossa P., Fabbi P., Manca V., Garibaldi S., Ghigliotti G., Barisione C., Altieri P., Patrone F., Brunelli C., and Barsotti A. Doxorubicin-induced expression of LOX-1 in H9c2 cardiac muscle cells and its role in apoptosis. Biochem. Biophys. Res. Commun. 335 (2005) 188-196
22. Menna P., Salvatorelli E., and Minotti G. Doxorubicin degradation in cardiomyocytes. J. Pharmacol. Exp. Ther. 322 (2007) 408-419
23. Gianni L., Vigano L., Locatelli A., Capri G., Giani A., Tarenzi E., and Bonadonna G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol. 15 (1997) 1906-1915
24. Hasinoff B.B., Patel D., and Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic. Biol. Med. 35 (2003) 1469-1479
25. Ryter S.W., Alam J., and Choi A.M. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86 (2006) 583-650
26. Igarashi K., and Sun J. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid. Redox Signal. 8 (2006) 107-118
27. Kim H.P., Ryter S.W., and Choi A.M. CO as a cellular signaling molecule. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 411-449
28. L'Ecuyer T., Horenstein M.S., Thomas R., and Vander Heide R. Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies. Mol. Genet. Metab. 74 (2001) 370-379
29. Li K., Sung R.Y., Huang W.Z., Yang M., Pong N.H., Lee S.M., Chan W.Y., Zhao H., To M.Y., Fok T.F., Li C.K., Wong Y.O., and Ng P.C. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113 (2006) 2211-2220
30. Lyu Y.L., Kerrigan J.E., Lin C.P., Azarova A.M., Tsai Y.C., Ban Y., and Liu L.F. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 67 (2007) 8839-8846
31. Turakhia S., Venkatakrishnan C.D., Dunsmore K., Wong H., Kuppusamy P., Zweier J.L., and Ilangovan G. Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H3111-3121
32. Suliman H.B., Carraway M.S., Ali A.S., Reynolds C.M., Welty-Wolf K.E., and Piantadosi C.A. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J. Clin. Invest. 117 12 (2007) 3730-3741
33. Ryter S.W., and Choi A.M. Therapeutic applications of carbon monoxide in lung disease. Curr. Opin. Pharmacol. 6 (2006) 257-262
34. Ollinger R., Wang H., Yamashita K., Wegiel B., Thomas M., Margreiter R., and Bach F.H. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid. Redox Signal. 9 (2007) 2175-2185
35. Konorev E.A., Kotamraju S., Zhao H., Kalivendi S., Joseph J., and Kalyanaraman B. Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic. Biol. Med. 33 (2002) 988
36. Kweon M.H., Adhami V.M., Lee J.S., and Mukhtar H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem. 281 (2006) 33761-33772
37. Motterlini R. Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities. Biochem. Soc. Trans. 35 (2007) 1142-1146
38. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., and Opipari Jr. A.W. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 276 (2001) 48921-48929
39. Pham C.G., Bubici C., Zazzeroni F., Knabb J.R., Papa S., Kuntzen C., and Franzoso G. Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol. Cell. Biol. 27 (2007) 3920-3935
40. Kim Y., Ma A.G., Kitta K., Fitch S.N., Ikeda T., Ihara Y., Simon A.R., Evans T., and Suzuki Y.J. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 63 (2003) 368-377
41. Ishikawa M., Numazawa S., and Yoshida T. Redox regulation of the transcriptional repressor Bach1. Free Radic. Biol. Med. 38 (2005) 1344-1352
42. Pham C.G., Bubici C., Zazzeroni F., Papa S., Jones J., Alvarez K., Jayawardena S., De Smaele E., Cong R., Beaumont C., Torti F.M., Torti S.V., and Franzoso G. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119 (2004) 529-542